Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC

Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC

Three chemical series of heterocyclic small molecules were designed and synthesized as the 3rd generation EGFR inhibitors. Detailed structure-activity relationship (SAR) studies and lead optimization (from 1a to 4d) were descripted. With the support of molecular modeling and evaluation through bioch...

Full description

Bibliographic Details
Main Authors: Long Mao, Wei Tang, Xiaoying Zhang, Jia Liu, Yile Chen, Yuning Hua, Bojie Weng, Xiaopeng Mo, Yimei Bao, Li Teng, Lijun Xu, Yuren Zhang, Jian Wu, Guanglin Zhou, Bin Liang, Changxu Xu, Biao Xi, Li Zhao, Rongda Xu, Che Fang, Wanhong Xu, Xiaobo Wang, Xiao Xu
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Medicine in Drug Discovery
Subjects:
Discovery
Design and synthesis
SAR study
Abivertinib (AC0010)
EGFR TKI
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2590098620300221

Internet

http://www.sciencedirect.com/science/article/pii/S2590098620300221

Similar Items